Phospholipase A2 Receptor Monitoring, Serum


Abbrev Code:PLA2M   
Order Code:LAB8270Order Name:Phospholipase A2 Receptor Monitoring
Synonyms:PLA2M; PLA2R; Anti-PLA2R
Methodology:Enzyme-Linked Immunosorbent Assay
CPT Codes: 83250 x1, 83520 x1
Turnaround Time:Specimen sent to reference laboratory Monday-Friday; results are reported within 8 days.
Compliance:

This test has been cleared, approved or is exempt by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.



Collection Instructions

Specimen:Blood
Optimal Volume:3 mL
Minimum\Peds Volume:1.2 mL
Container:Red or gold (gel)
Alternate Containers: Red (no gel)


Processing and Shipping

Specimen Processing:Centrifuge and aliquot 1 mL; 0.5 mL minimum. Store refrigerated.
Shipping Instructions:Ship at refrigerated temperature.
Stability:8 hours at room temperature; 14 days refrigerated (preferred) or frozen.
Test Performed at or Referral Lab Lab Sendouts  (Mayo Medical Laboratories)
Referral Lab number:PLA2M


Interpretive

Reference Range:<14 RU/mL: Negative
14 to 19 RU/mL: Borderline
≥20 RU/mL: Positive
Limitations:Absence of circulating anti-phospholipase A2 receptor autoantibodies does not rule out a diagnosis of primary MN.
Use:
  • Distinguishing primary from secondary membranous nephropathy
  • Monitoring patients with membranous nephropathy, over time, for trends in anti-phospholipase A2 receptor antibody levels.
  • This test can be used to identify whether a specific autoantibody is present in a patient with biopsy proven membranous nephropathy or in a patient without a renal biopsy but with a clinical picture consistent with membranous nephropathy.
  • Anti-phospholipase A2 receptor (PLA2R) antibodies are highly specific for the diagnosis of primary membranous nephropathy.
  • If a patient is already known to have anti-phospholipase A2 receptor positive membranous nephropathy, this test can be used to monitor response to treatment or detect relapse.
  • As many as 70% to 75% of patients with primary membranous nephropathy are positive for anti-PLA2R.
  • A titer increase, decrease, or disappearance generally precedes a change in clinical status.


Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
systemlabguide@fairview.org for TestID: 6770"